Had a quick read of it. Looks pretty dodgy. You have to pretend...

Had a quick read of it. Looks pretty dodgy. You have to pretend not to be Aussie based to read it.

They claim "analytic technology lags far behind the competition" and sing the praises of Eagleview. They also claim sales to insurers, about 41% of the total, may be challenged in a potential patent dispute with key U.S. competitor in some link to the AFR which does not work. Looks like an old story we would be aware of.

Could not find any hard info that has me worried.